Reply.
作者信息
Arase Yoshitaka, Kagawa Tatehiro, Tanaka Atsushi
机构信息
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan.
Division of Gastroenterology and Hepatology, Tokai University Oiso Hospital, Oisomachi, Japan.
出版信息
Hepatology. 2020 Jul;72(1):360-361. doi: 10.1002/hep.31084.
Abstract
摘要
相似文献
1
Reply.回复。
Hepatology. 2020 Jul;72(1):360-361. doi: 10.1002/hep.31084.
2
Reply.回复。
Hepatology. 2020 Mar;71(3):1132-1133. doi: 10.1002/hep.30999. Epub 2020 Mar 4.
3
Letter to the Editor: Might Denosumab Fit in Primary Biliary Cholangitis Treatment?致编辑的信：地诺单抗是否适用于原发性胆汁性胆管炎的治疗？
Hepatology. 2020 Jul;72(1):359-360. doi: 10.1002/hep.31085.
4
Denosumab treatment in postmenopausal women with osteoporosis - Authors' reply.
Lancet Diabetes Endocrinol. 2017 Oct;5(10):768-769. doi: 10.1016/S2213-8587(17)30288-7.
5
Letter to the Editor: Bone Health and Denosumab Treatment in Autoimmune Liver Diseases: A Possible Involvement of Physical Activity.
Hepatology. 2020 Mar;71(3):1131-1132. doi: 10.1002/hep.31001. Epub 2020 Mar 5.
6
Reply.回复。
Arthritis Rheumatol. 2019 Oct;71(10):1771-1772. doi: 10.1002/art.41013. Epub 2019 Sep 2.
7
In Reply to the Letter to the Editor: The Efficacy of Denosumab for Prevention of Early Periprosthetic Bone Loss After Cementless Total Hip Arthroplasty.致编辑的信的回复：地诺单抗预防非骨水泥型全髋关节置换术后早期假体周围骨丢失的疗效
J Bone Miner Res. 2020 May;35(5):1000. doi: 10.1002/jbmr.3981. Epub 2020 Mar 2.
8
One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study.不同抗骨质疏松药物的一年和两年持续治疗情况：一项回顾性队列研究。
Osteoporos Int. 2017 Oct;28(10):2997-3004. doi: 10.1007/s00198-017-4144-7. Epub 2017 Jul 16.
9
Osteonecrosis of the jaw in patients transitioning from bisphosphonates to denosumab treatment for osteoporosis.骨质疏松症患者从双膦酸盐类药物转换为地诺单抗治疗过程中的颌骨骨坏死。
Odontology. 2018 Oct;106(4):469-480. doi: 10.1007/s10266-018-0362-5. Epub 2018 Apr 30.
10
Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study.绝经后骨质疏松症妇女使用地舒单抗 24 个月的持续治疗：一项前瞻性队列研究结果。
Arch Osteoporos. 2018 Aug 7;13(1):85. doi: 10.1007/s11657-018-0491-z.
本文引用的文献
1
Efficacy and Safety of 3-Year Denosumab Therapy for Osteoporosis in Patients With Autoimmune Liver Diseases.3年地诺单抗治疗自身免疫性肝病患者骨质疏松症的疗效与安全性
Hepatology. 2020 Feb;71(2):757-759. doi: 10.1002/hep.30904. Epub 2019 Oct 10.
2
Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.辅助地舒单抗用于激素受体阳性乳腺癌（ABCSG-18）绝经后患者：一项随机、双盲、安慰剂对照、3 期临床试验的无病生存结果。
Lancet Oncol. 2019 Mar;20(3):339-351. doi: 10.1016/S1470-2045(18)30862-3. Epub 2019 Feb 19.
3
Roles of the RANKL-RANK axis in antitumour immunity - implications for therapy.RANKL-RANK 轴在抗肿瘤免疫中的作用及其治疗意义。
Nat Rev Clin Oncol. 2018 Nov;15(11):676-693. doi: 10.1038/s41571-018-0095-y.
4
Quantitation of the Rank-Rankl Axis in Primary Biliary Cholangitis.原发性胆汁性胆管炎中Rank-Rankl轴的定量分析。
PLoS One. 2016 Sep 15;11(9):e0159612. doi: 10.1371/journal.pone.0159612. eCollection 2016.
5
Combination Anti-CTLA-4 and Anti-RANKL in Metastatic Melanoma.抗CTLA-4与抗RANKL联合用于转移性黑色素瘤
J Clin Oncol. 2016 Apr 20;34(12):e104-6. doi: 10.1200/JCO.2013.51.3572. Epub 2014 Oct 13.
Zotero 插件